12:08 PM EDT, 10/17/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) is positioning for potential "price wars" in the continuous glucose monitoring, or CGM, market with "price flexibility" tied to basal approvals outside the US, Oppenheimer said in a note Thursday.

The company's integration of Volt pulsed field ablation into the EnSite mapping system offers the company "a competitive advantage, though lack of dual-energy somewhat negative," Oppenheimer said.

Abbott Laboratories ( ABT ) reported Q3 adjusted earnings Wednesday of $1.21 per diluted share on revenue of $10.64 billion.

The company delivered a solid Q3 with GAAP EPS meeting expectations and revenue exceeding the $10.55 billion consensus estimate but below Oppenheimer's $10.79 billion forecast, the firm said.

The Medical Devices segment saw a 13.3% organic revenue increase to $4.75 billion, driven by growth in continuous glucose monitoring, cardiac rhythm management, and electrophysiology, Oppenheimer noted.

Oppenheimer rated Abbott stock outperform with a $130 price target.

Price: 117.53, Change: -0.29, Percent Change: -0.25